BTTC Debuts on Nasdaq Following Titan Pharmaceuticals and Black Titan Merger—Strategic Shift Paves Way for Expansion

Seamless Merger Transition Positions BTTC for Growth

With the closing of the merger between Titan Pharmaceuticals, Inc. and Black Titan Corporation (alongside TalenTec Sdn. Bhd.), the new entity now trades on Nasdaq under the ticker symbol BTTC. Effective October 1, 2025, Titan Pharmaceuticals has become a wholly owned subsidiary of Black Titan, setting in motion a structural shift aimed at strengthening innovation and enabling global expansion.

This transition was implemented smoothly—each share of Titan’s common stock automatically converted to Black Titan ordinary shares on a one-for-one basis. Trading in Titan shares ceased at market close on October 1, 2025, with Black Titan shares beginning on Nasdaq the following day. This structure allows investors continuity and direct exposure to the combined company’s strategy from day one.

Leadership Emphasizes Vision and Scale

Chay W. J., CEO of Black Titan, signaled a renewed drive toward international ambitions and value creation for stakeholders. “This merger represents more than a structural change; it's the beginning of a new chapter of innovation and global expansion,” he stated, reflecting confidence in Black Titan’s vision and capabilities post-merger.

Merger Strategy: Direct Market Exposure and Growth Outlook

The strategic merger was orchestrated through a share exchange, offering TTNP holders new BTTC shares without dilution or additional requirements. This seamless transition provides existing shareholders uninterrupted participation and removes traditional risks often associated with merger logistics.

ARC Group Ltd. acted as the exclusive financial advisor for the transaction, ensuring the combined company was well-structured for both public market scrutiny and institutional confidence. The arrangement is set up to capture synergies and enable Black Titan’s vision of international growth, leveraging Titan Pharmaceuticals’ operational history and TalenTec’s global connections.

Forward-Looking Vision with Cautious Optimism

The merger brings a blend of biotech and growth strategies, signaling to investors that BTTC is positioned to seek out transformative opportunities. Still, management cautions that forward-looking statements in the release are subject to risks typical in high-growth transitions—market expectations, integration challenges, and strategic execution remain critical factors to monitor.

Key Takeaway: Direct Line to a Growth-Focused Story

For investors and market watchers, BTTC’s Nasdaq debut is not just a rebranding, but a doorway to Black Titan’s expanded strategy. With leadership committed to innovation and the mechanics of the merger simplifying shareholder participation, the stage is set for the next chapter in this growth-focused story.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI